Etiology-Dependent Microbiome Differences in Hepatocellular Carcinoma Development DOI Open Access
Nevena Todorović, Serena Martinelli, Giulia Nannini

et al.

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(24), P. 13510 - 13510

Published: Dec. 17, 2024

Chronic liver disease is characterised by persistent inflammation, tissue damage, and regeneration, which leads to steatosis, fibrosis, and, lastly, cirrhosis hepatocellular carcinoma (HCC). HCC, the most prevalent form of primary cancer, one leading causes cancer-related mortality worldwide. The gut microbiota plays a fundamental role in human physiology, disturbances its critical balance are widely recognised as contributors various pathological conditions, including chronic diseases, both infectious non-infectious nature. Growing interest research has recently shifted focus towards study intratumoural microbiota, referred “oncobiome”, can significantly impact development progression HCC. In this review, we discuss existing provide an overview influence on viral hepatitis, particularly shaping caused hepatitis B C viruses. We also explore microbial dysbiosis contribution silent dangerous non-alcoholic fatty disease. Additionally, address alcohol interaction with tracing pathway from inflammation cancer. review emphasises common etiologies carcinoma.

Language: Английский

Current Therapeutic Landscape for Metabolic Dysfunction-Associated Steatohepatitis DOI Open Access

Arun George Devasia,

Adaikalavan Ramasamy, Chen Huei Leo

et al.

International Journal of Molecular Sciences, Journal Year: 2025, Volume and Issue: 26(4), P. 1778 - 1778

Published: Feb. 19, 2025

In recent years, “metabolic dysfunction-associated steatotic liver disease” (MASLD) has been proposed to better connect disease metabolic dysfunction, which is the most common chronic worldwide. MASLD affects more than 30% of individuals globally, and it diagnosed by combination hepatic steatosis obesity, type 2 diabetes, or two risk factors. begins with buildup extra fat, often greater 5%, within liver, causing hepatocytes become stressed. This can proceed a severe form, steatohepatitis (MASH), in 20–30% people, where inflammation causes tissue fibrosis, limits blood flow over time. As fibrosis worsens, MASH may lead cirrhosis, failure, even cancer. While pathophysiology not fully known, current “multiple-hits” concept proposes that dietary lifestyle factors, genetic epigenetic factors contribute elevated oxidative stress inflammation, fibrosis. review article provides an overview pathogenesis evaluates existing therapies as well pharmacological drugs are currently being studied clinical trials for MASH.

Language: Английский

Citations

1
Exploring Extracellular Vesicles: A Novel Approach in Nonalcoholic Fatty Liver Disease DOI

Ana Isabel Vigil Medina,

Mengdie Shi,

Yanyan Wang

et al.

Journal of Agricultural and Food Chemistry, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 23, 2025

Nonalcoholic fatty liver disease (NAFLD) represents an increasing public health concern. The underlying pathophysiological mechanisms of NAFLD remains unclear, and as a result, there is currently no specific therapy for this condition. However, recent studies focus on extracellular vesicles (EVs) novelty in their role cellular communication. An imbalance the gut microbiota composition may contribute to progression NAFLD, making gut-liver axis promising target therapeutic strategies. This review aims provide comprehensive overview EVs NAFLD. Additionally, exosome-like nanovesicles derived from plants (PELNs) probiotics-derived (postbiotics) have demonstrated potential re-establish intestinal equilibrium modulate microbiota, thus offering alleviate via axis. Further research needed using multiple omics approaches comprehensively characterize cargo including protein, metabolites, genetic material packaged, biological activities diverse microbes plants.

Language: Английский

Citations

0
Sodium alginate alleviated isoniazid-induced liver injury by modulating fecal metabolites and gut microbiota DOI
Xinfang Wang,

Jingkai Zhang,

Xia Xin

et al.

International Journal of Biological Macromolecules, Journal Year: 2025, Volume and Issue: unknown, P. 141149 - 141149

Published: Feb. 1, 2025

Language: Английский

Citations

0
Alleviating effect of Lactobacillus fermentum E15 on hyperlipidemia and hepatic lipid metabolism in zebrafish fed by a high-fat diet through the production of short-chain fatty acids DOI Creative Commons
Yishu Chen, Kangdi Zheng,

Yang Leng

et al.

Frontiers in Nutrition, Journal Year: 2025, Volume and Issue: 12

Published: March 3, 2025

Introduction Hyperlipidemia is regarded as one of the crucial factors leading to atherosclerosis and other cardiovascular diseases. Gut microbiota plays an important role in regulating host lipid metabolism. Nevertheless, exact mechanisms behind this remain unclear. Methods In present study, a hyperlipidemic zebrafish model was established using high-cholesterol diet (HCD) evaluate anti-hyperlipidemic effects Lactobacillus fermentum E15 ( L. E15). Results showed that effectively reduced accumulation blood vessels liver HCD-fed larvae. Meanwhile, improved abnormal levels, normalized enzyme activity. Real-time quantitative polymerase chain reaction (RT-qPCR) analysis revealed downregulated expression sterol regulatory element-binding factor (SREBP-1), peroxisome proliferator-activated receptor-gamma (PPAR- γ ), fatty acid synthase (Fasn), while upregulated receptor-alpha α ). Additionally, metabolomic produced series short-chain acids (SCFAs), including acetic acid, propionic butyric isovaleric acid. Notably, contributed reduction droplet contrast, blocking G-protein coupled receptor 43 (GPR43) with pertussis toxin (PTX) abolished on reducing RT-qPCR results further suggested both promoted GPR43 leptin A, which inhibited by PTX. Conclusion These findings alleviates HCD-induced hyperlipidemia activating through SCFAs.

Language: Английский

Citations

0
The Role of Short-Chain Fatty Acids in Metabolic Dysfunction-Associated Steatotic Liver Disease and Other Metabolic Diseases DOI Creative Commons

Eliane Münte,

Phillipp Hartmann

Biomolecules, Journal Year: 2025, Volume and Issue: 15(4), P. 469 - 469

Published: March 22, 2025

With its increasing prevalence, metabolic dysfunction-associated steatotic liver disease (MASLD) has emerged as a major global public health concern over the past few decades. Growing evidence proposed microbiota-derived metabolites short-chain fatty acids (SCFAs) potential factor in pathophysiology of MASLD and related conditions, such obesity type 2 diabetes mellitus (T2DM). By influencing key pathways involved energy homeostasis, insulin sensitivity, inflammation, SCFAs play an important role gut microbiota composition, intestinal barrier function, immune modulation, direct signaling. Furthermore, recent animal human studies on therapeutic strategies targeting demonstrate their for treating these disorders.

Language: Английский

Citations

0
Role of short-chain fatty acids in non-alcoholic fatty liver disease and potential therapeutic targets DOI Creative Commons
Xiang Qin,

Mengyao Chen,

Beihui He

et al.

Frontiers in Microbiology, Journal Year: 2025, Volume and Issue: 16

Published: April 3, 2025

Non-alcoholic fatty liver disease (NAFLD) is increasing worldwide and has become the greatest potential risk for cirrhosis hepatocellular carcinoma. The metabolites produced by gut microbiota act as signal molecules that mediate interaction between microorganisms host have biphasic effects on human health. its metabolites, short-chain acids (SCFAs), been discovered to ameliorate many prevalent diseases, including NAFLD. Currently, SCFAs attracted widespread attention therapeutic targets NAFLD, but mechanism of action not fully elucidated. This article summarizes mechanisms regulate metabolism glucose lipid, maintain intestinal barrier, alleviate inflammatory response, improve oxidative stress in order provide a reference clinical application.

Language: Английский

Citations

0
Inflammation in MASLD Progression and Cancer DOI Creative Commons
Yeon Soo Kim,

Y. C. Park,

Hyunsoo Rho

et al.

JHEP Reports, Journal Year: 2025, Volume and Issue: unknown, P. 101414 - 101414

Published: April 1, 2025

Language: Английский

Citations

0
Hypogonadism and nonalcoholic fatty liver disease DOI

Kasiani Papadimitriou,

Athanasios Mousiolis,

Gesthimani Mintziori

et al.

Endocrine, Journal Year: 2024, Volume and Issue: 86(1), P. 28 - 47

Published: May 21, 2024

Language: Английский

Citations

3
Quercetin: A Promising Candidate for the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) DOI Creative Commons

Julia Markowska,

Kamila Kasprzak‐Drozd, Przemysław Niziński

et al.

Molecules, Journal Year: 2024, Volume and Issue: 29(22), P. 5245 - 5245

Published: Nov. 6, 2024

Metabolic dysfunction-associated steatotic liver disease (MASLD) represents a chronic disease. The development of MASLD is influenced by multitude diseases associated with modern lifestyles, including but not limited to diabetes mellitus, hypertension, hyperlipidaemia and obesity. These conditions are often consequences the adoption unhealthy habits, namely sedentary lifestyle, lack physical activity, poor dietary choices excessive alcohol consumption. treatment primarily based on modifying patient's lifestyle pharmacological intervention. Despite absence FDA-approved agents for MASLD, several potential therapeutic modalities have demonstrated efficacy in reversing histopathological features Among botanical ingredients belonging flavonoid group quercetin (QE). QE has been possess number beneficial physiological effects, anti-inflammatory, anticancer antifungal properties. Additionally, it functions as natural antioxidant. Preclinical evidence indicates that may play role reducing damage improving metabolic health. Early human studies also suggest be an effective due its antioxidant, lipid-regulating This review aims summarize available information effects MASLD.

Language: Английский

Citations

2
Mediterranean diet for the management of metabolic dysfunction‐associated steatotic liver disease in non‐Mediterranean, Western countries: What's known and what's needed? DOI Creative Commons
Ayesha Sualeheen, Sze‐Yen Tan, Ekavi N. Georgousopoulou

et al.

Nutrition Bulletin, Journal Year: 2024, Volume and Issue: unknown

Published: Sept. 11, 2024

Abstract Metabolic dysfunction‐associated steatotic liver disease (MASLD) is the most common worldwide, affecting 30% of population in Western countries. MASLD considered hepatic manifestation metabolic syndrome, pathophysiologically underpinned by insulin resistance and frequently co‐exists with hypertension, central obesity dyslipidaemia. Currently, safe effective pharmacotherapies for are limited, making weight loss lifestyle changes mainstay therapy. A Mediterranean diet (MedDiet) has emerged as an dietary pattern preventing managing MASLD, but studies have been conducted countries, necessitating further investigation into its benefits populations. Additionally, effect holistic multimodal interventions, including physical activity combined MedDiet, not well established. Finally, MASLD's widespread prevalence rapid growth require improved accessibility to interventions. Digital health delivery platforms, designed remote access, could be a promising approach providing timely support individuals MASLD. This narrative review summarises current evidence related effects MedDiet Western, multicultural populations includes detailed description composition, prescription adherence interventions terms how they applied. The role or exercise prescribed combination will also reviewed. recommendations design inform future randomised controlled trials facilitate optimal management outlined.

Language: Английский

Citations

2